Page 259 - 2020_02-Haematologica-web

Obstetric APS and cancer
Table 1. Characteristics of the patients at baseline and at follow-up. Control grou
Thrombophilia group
279
29 (4) [18-44] 12 (4.3%)
25.9 (4.2) [13.5-34.1] 29 (10.4%)
3 (1.1%)
227 (81.4%) 37 (13.2%) 12 (4.3%) 3 (1.1%)
93 (33.3%) 186 (66.6%) 185 (66.3%) 94 (33.7%)
4 (1.4%)
58 (20.8%) 30 (10.8%) 8 (2.9%) 13 (4.7%) 11 (3.9%) 2 (0.7%)
29 (10.4%) 46 (16.5%)
0
0
0
0
0
0
176 (63.1%) 103 (36.9%)
APS group
517
29 (4) [16-41] 15 (2.9%)
26.0 (4.6) [15.3-37.0] 60 (11.6%)
5 (1%)
420 (81.2%) 69 (13.4%) 22 (4.2%) 6 (1.2%)
206 (39.8%) 311 (60.2%) 342 (66.1%) 175 (33.9%)
32 (6.2%)
117 (22.6%) 50 (9.7%) 17 (3.3%) 31 (6.0%) 27 (5.2%) 6 (1.2%)
12 (2.3%) 53 (10.3%)
319 (61.7%) 244 (47.2%) 372 (71.9%) 114 (22.1%) 210 (40.6%) 149 (28.8%) 11 (2.1%)
6 (1.2%)
6251 (1768) [1085-8030] 6 (1.2%)
29 (5.6%)
21 (4.1%)
46 (7) [30-61]
Number
Age, years Age >35 years
Body mass index, kg/m-2 >30
<18.5
Ethnicity Caucasian-European Caucasian-North African Black African
Asian
PL subtype
Embryonic PL at <10 WG Fetal PL at ≤10 WG Primary PL
Secondary PL
Inflammatory disease
Risk factors for vascular diseases Varicose veins
Current smoker
Hypertension Hypercholesterolemia Hypertriglyceridemia
Diabetes mellitus
Positive history in a first-degree relative Venous thromboembolism Atherothrombosis
Prevalence of thrombophilia laboratory markers Positive for LA
Positive for aCL-G
Positive for aCL-M
Positive for aβ2GP1-G Positive for aβ2GP1-M Positive for LA+aCL+ aβ2GP1 Positive for F5 rs6025 Positive for F2 rs1799963
Follow-up duration, days
Lost to follow-up
Deceased
Deceased, non-cancer-related
Age, years
Body mass index, kg/m2 >30
<18.5
Cancer history, first-degree relatives Current smokers
Inflammatory disease
Diabetes mellitus
Number of new pregnancies
Outcomes of new pregnancies At least one living neonate Embryonic PL <10 WG
Fetal death ≥10 WG Stillbirth
Neonatal death
796
30 (5) [17-44] 43 (5.4%)
25.6 (4.5) [15.3-36.1] 78 (9.8%)
12 (1.5%)
647 (81.3%) 106 (13.3%) 36 (4.5%) 7 (0.9%)
483 (60.7%) 313 (39.3%) 549 (68.9%) 247 (31.1%)
7 (0.9%)
187 (23.5%) 83 (10.4%) 19 (2.4%) 42 (5.3%) 34 (4.3%) 11 (1.4%)
15 (1.9%) 96 (12.1%)
0 0 0 0 0 0 0 0
BASELINE
FOLLOW-UP (data obtained during the last evaluation)
6209 (1758) [371-8029] 23 (2.9%)
13 (1.6%)
8 (1.0%)
46 (7) [27-64]
6166 (1770) [1294-8011] 8 (2.9%)
5 (1.8%)
4 (1.4%)
46 (6) [32-63]
27.6 (4.5) [17.9-40.5] 44 (15.8%)
12 (4.3%)
52 (18.6%) 89 (31.9%) 10 (3.6%) 10 (3.6%) 2 [1-3]
233 (83.5%) 96 (34.4%) 37 (13.3%) 15 (5.4%) 6 (2.2%)
27.8
(4.7) [17.4-41.1] 121 (15.2%)
31 (3.9%) 164 (20.6%) 237 (29.8%) 23 (2.9%) 27 (3.4%) 2 [1-3]
695 (87.3%) 297 (37.3%) 101 (12.7%) 36 (4.5%) 12 (1.5%)
28.0
(4.9) [18.1-40.8] 82 (15.9%)
20 (3.9%) 114 (22.1%) 163 (31.5%) 64 (12.4%) 21 (4.1%) 2 [1-4]
417 (80.7%) 198 (38.3%) 85 (16.4%) 46 (8.9%) 27 (5.2%)
continued on the next page
haematologica | 2020; 105(2)
493